ZP4207(Dasiglucagon) Administered to T1D Patients to Assess the PK and PD Compared to Marketed Glucagon
Status:
Completed
Trial end date:
2017-04-05
Target enrollment:
Participant gender:
Summary
The trial is a single-centre, randomised, sequential, cross-over trial assessing
pharmacokinetic and pharmacodynamic responses after micro-doses of ZP4207 (dasiglucagon*)
administered subcutaneously to patients with type 1 diabetes mellitus under euglycaemic and
hypoglycaemic conditions and compared to marketed glucagon.
*dasiglucagon is the proposed International Nonproprietary Name (pINN) for ZP4207